{"id":7622,"date":"2024-03-20T10:28:18","date_gmt":"2024-03-20T02:28:18","guid":{"rendered":"https:\/\/flcube.com\/?p=7622"},"modified":"2024-10-18T10:30:18","modified_gmt":"2024-10-18T02:30:18","slug":"zuellig-pharma-expands-commercialization-deal-for-karo-healthcares-lamisil-in-asian-markets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=7622","title":{"rendered":"Zuellig Pharma Expands Commercialization Deal for Karo Healthcare&#8217;s Lamisil in Asian Markets"},"content":{"rendered":"\n<p>Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement with Sweden-based Karo Healthcare. According to the new terms, Zuellig will serve as the exclusive commercialization partner for Karo&#8217;s over-the-counter (OTC) anti-fungal treatment Lamisil (terbinafine hydrochloride) across key Asian markets, including Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Vietnam. The financial details of the deal have not been disclosed.<\/p>\n\n\n\n<p>Karo Healthcare boasts a comprehensive portfolio of more than 80 different brands spanning OTC and prescription drugs, addressing various disease areas such as skin health, intimate health, digestive health, foot health, wellness, pain relief, cough and cold, and specialty products. Zuellig Pharma&#8217;s extensive network across Asia encompasses healthcare professionals and retail pharmacies, providing a robust platform for the commercialization of Karo&#8217;s products.<\/p>\n\n\n\n<p>The two companies are no strangers to collaboration, having partnered in 2019 for Zuellig to offer commercial support for Karo&#8217;s portfolio in the Philippines, Vietnam, Singapore, and Indonesia. The development of Lamisil under the new agreement will be managed by Zuellig\u2019s commercial division, ZP Therapeutics, signaling a deepening of the partnership and a commitment to expanding access to Karo&#8217;s anti-fungal treatment in the region.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[27,78,284],"class_list":["post-7622","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-finanical-reports","tag-otc-retail","tag-zuellig-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zuellig Pharma Expands Commercialization Deal for Karo Healthcare&#039;s Lamisil in Asian Markets - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement with Sweden-based Karo Healthcare. According to the new terms, Zuellig will serve as the exclusive commercialization partner for Karo&#039;s over-the-counter (OTC) anti-fungal treatment Lamisil (terbinafine hydrochloride) across key Asian markets, including Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Vietnam. The financial details of the deal have not been disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=7622\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zuellig Pharma Expands Commercialization Deal for Karo Healthcare&#039;s Lamisil in Asian Markets\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=7622\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-20T02:28:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-18T02:30:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7622#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7622\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zuellig Pharma Expands Commercialization Deal for Karo Healthcare&#8217;s Lamisil in Asian Markets\",\"datePublished\":\"2024-03-20T02:28:18+00:00\",\"dateModified\":\"2024-10-18T02:30:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7622\"},\"wordCount\":212,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"OTC \\\/ retail\",\"Zuellig Pharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=7622#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7622\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=7622\",\"name\":\"Zuellig Pharma Expands Commercialization Deal for Karo Healthcare's Lamisil in Asian Markets - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-03-20T02:28:18+00:00\",\"dateModified\":\"2024-10-18T02:30:18+00:00\",\"description\":\"Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement with Sweden-based Karo Healthcare. According to the new terms, Zuellig will serve as the exclusive commercialization partner for Karo's over-the-counter (OTC) anti-fungal treatment Lamisil (terbinafine hydrochloride) across key Asian markets, including Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Vietnam. The financial details of the deal have not been disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7622#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=7622\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=7622#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zuellig Pharma Expands Commercialization Deal for Karo Healthcare&#8217;s Lamisil in Asian Markets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zuellig Pharma Expands Commercialization Deal for Karo Healthcare's Lamisil in Asian Markets - Insight, China&#039;s Pharmaceutical Industry","description":"Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement with Sweden-based Karo Healthcare. According to the new terms, Zuellig will serve as the exclusive commercialization partner for Karo's over-the-counter (OTC) anti-fungal treatment Lamisil (terbinafine hydrochloride) across key Asian markets, including Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Vietnam. The financial details of the deal have not been disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=7622","og_locale":"en_US","og_type":"article","og_title":"Zuellig Pharma Expands Commercialization Deal for Karo Healthcare's Lamisil in Asian Markets","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=7622","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-03-20T02:28:18+00:00","article_modified_time":"2024-10-18T02:30:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=7622#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=7622"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zuellig Pharma Expands Commercialization Deal for Karo Healthcare&#8217;s Lamisil in Asian Markets","datePublished":"2024-03-20T02:28:18+00:00","dateModified":"2024-10-18T02:30:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=7622"},"wordCount":212,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","OTC \/ retail","Zuellig Pharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=7622#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=7622","url":"https:\/\/flcube.com\/?p=7622","name":"Zuellig Pharma Expands Commercialization Deal for Karo Healthcare's Lamisil in Asian Markets - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-03-20T02:28:18+00:00","dateModified":"2024-10-18T02:30:18+00:00","description":"Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement with Sweden-based Karo Healthcare. According to the new terms, Zuellig will serve as the exclusive commercialization partner for Karo's over-the-counter (OTC) anti-fungal treatment Lamisil (terbinafine hydrochloride) across key Asian markets, including Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Vietnam. The financial details of the deal have not been disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=7622#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=7622"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=7622#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zuellig Pharma Expands Commercialization Deal for Karo Healthcare&#8217;s Lamisil in Asian Markets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7622","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7622"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7622\/revisions"}],"predecessor-version":[{"id":7623,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/7622\/revisions\/7623"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}